38 reports

End User 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 CAGR D iag nosti c Ce nte rs ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ##. ## ## ## ##. ## % Hosp ita ls a nd Cli ni cs ##. ## ##

  • Blood Disease
  • Forecast
  • Market Size
  • Illumina, Inc.
  • Natera, Inc.

Hemophilia

4385 5000 3900
  • HIV AND HCV INFECTION ARE COMMON IN OLDER HEMOPHILIA PATIENTS

However, the initiation of HCV testing along with improved donor screening protocols and improved factor product safety have greatly reduced the risk of HCV transmission from plasma-derived clotting factor (Posthouwer et al., 2007).

  • Blood Disease
  • European Union
  • Japan
  • North America
  • United States

The primary outcome measures of this study are to asses the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Blood Disease
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

Abbott launched RealTime HCV Genotype II test, a HCV genotyping test for patients in the U. S.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • North America
  • United States

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Oncology
  • Ultrasound
  • Merck & Co., Inc.

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Blood Disease
  • Hepatitis
  • Lung Cancer
  • United States
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Lung Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • Abbott Diagnostics Pipeline Products Overview

Lung Cancer PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PRODUCT OVERVIEW PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER - PRODUCT STATUS PD-##/ PDL-

  • Blood Disease
  • Leukemia
  • Lung Cancer
  • Therapy
  • United States

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Digestive System Disorder
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Ultrasound

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

BIODESIX VERISTRAT TEST IS A PREDICTIVE AND PROGNOSTIC BLOOD-BASED PROTEOMIC TEST FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Oncology
  • Ultrasound
  • Merck & Co., Inc.

Median OS was ##. ## mo (median OS was not reached in the HCV and HBV cohorts) and the ##-mo OS rate was ##. ## percent.

  • Blood Disease
  • Cancer
  • Lung Cancer
  • United States
  • Eisai Co., Ltd.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Cancer
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Cancer
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

THE PRIMARY OUTCOME MEASURES OF THIS STUDY ARE TO ASSES THE ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, LABORATORY RESULTS (HEMATOLOGY, SERUM BLOOD CHEMISTRY, HEPATITIS TESTS, STANDARD URINALYSIS DIPSTICK ASSESSMENT, COAGULATION STUDIES)OR ASSESSMENT OF THE INCIDENCE OF PNEUMONITIS.

  • Blood Disease
  • Cancer
  • Lung Cancer
  • United States
  • Eisai Co., Ltd.

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Merck & Co., Inc.

Dr Graham Cooke, Chief Investigator of the STOP-HCV-## clinical trial, said: " We are pleased to incorporate the Genedrive IL##B point of care genotyping test in the STOP-HCV-## clinical trial which aims to identify key markers to guide the duration of

  • Blood Disease
  • Lung Cancer
  • Prostate Cancer
  • Ultrasound
  • United States

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies) or assessment of the incidence of pneumonitis.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Hospital
  • Lung Cancer
  • Therapy
  • Ultrasound

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Blood Disease
  • Lung Cancer
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Merck & Co., Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies) or assessment of the incidence of pneumonitis.

  • Blood Disease
  • Lung Cancer
  • Ultrasound
  • United States
  • Merck & Co., Inc.